Xenon's Loss Widens To $110.4 Million As Azetukalner Trials And Launch Preparations Cost More
Loss per share narrowed, while initial results from the completed depression-study enrollment are now expected in December.
Xenon Pharmaceuticals, which is developing azetukalner for epilepsy and depression, posted a third-quarter loss of $110.4 million, up from $90.9 million a year earlier, according to its SEC earnings filing Monday. Trials, preparations for a potential launch and staffing pushed expenses higher, even as the loss per share narrowed to $1.11 from $1.15.
A Bigger Bill, More Cash
Xenon spent $95.6 million on research and development, versus $77.1 million a year earlier, its earnings release showed. The main costs behind the increase were azetukalner studies in major depressive disorder and bipolar depression, manufacturing ahead of potential commercialization, the early-stage XEN1720 pain study and a larger workforce, including stock-based pay.
Administrative spending reached $24.4 million, compared with $19.3 million, as personnel costs, stock compensation and professional and consulting fees increased. Higher interest income helped absorb part of the expense increase: other income rose to $11.5 million from $6.1 million.
The smaller per-share loss came with a larger average share count: 99,765,663, versus 79,247,976 a year earlier. Across the first nine months, Xenon's net loss reached $323.5 million, compared with $240.6 million.
Xenon held $1.1535 billion in cash and securities on September 30, 2026, versus $586.0 million on December 31, 2025. Management expects that funding to cover operations into 2029 under its current plans.
December's Depression Test
Xenon has finished enrolling approximately 360 patients in its late-stage azetukalner study for major depressive disorder. Initial results are now expected in December 2026.
Ian Mortimer, Xenon's president and chief executive officer, said, “we are working toward our first Phase 3 data readout in psychiatry.”
That milestone follows a September 2026 decision to voluntarily pause new enrollment in the company's ongoing late-stage major depressive disorder and bipolar depression studies. Patients already enrolled continue to participate, including in extension studies.
Azetukalner's epilepsy program is moving along a separate path. Xenon submitted an FDA approval application for focal seizures in September 2026. Another late-stage focal-seizure study continues to enroll patients to support applications outside the U.S.; enrollment outside Japan is expected to finish in 2026. A late-stage study in primary generalized tonic-clonic seizures is also enrolling.
Xenon plans to begin a U.S. study in the first quarter of 2027 testing azetukalner as the first medicine added to an existing antiseizure treatment. The open-label study, in which participants know the treatment they receive, will have a 52-week treatment period.
Pain Programs Add To Development
Xenon's work extends beyond azetukalner to potential non-opioid pain treatments and Dravet syndrome, a form of epilepsy. It also collaborates with Neurocrine Biosciences on epilepsy drug development.
In October 2026, Xenon presented early-stage results for XEN1701 and XEN1120 at the International Association for the Study of Pain's World Congress on Pain. Both studies involved healthy adults, and Xenon described the findings as positive and the drugs as generally well tolerated. The company expects to start mid-stage acute-pain studies of both candidates in the first half of 2027.
XEN1720 remains in an early-stage study in healthy adults. Xenon is also conducting preclinical work toward human testing of its Dravet syndrome program. Its collaboration with Neurocrine includes an ongoing early-stage study of NBI-921355, with data expected in 2027.
The nearest scheduled clinical result is azetukalner's depression readout in December; the potential epilepsy launch remains dependent on FDA approval.
Sources
- 8-K Filing — Xenon Pharmaceuticals Inc. (XENE) — SEC EDGAR
- Exhibit xene-ex99_1.htm — Xenon Pharmaceuticals Inc. 8-K exhibit — SEC EDGAR
- Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance